Carregant...

Relationships between Signaling Pathway Usage and Sensitivity to a Pathway Inhibitor: Examination of Trametinib Responses in Cultured Breast Cancer Lines

Cellular signaling pathways involving mTOR, PI3K and ERK have dominated recent studies of breast cancer biology, and inhibitors of these pathways have formed a focus of numerous clinical trials. We have chosen trametinib, a drug targeting MEK in the ERK pathway, to address two questions. Firstly, do...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Leung, Euphemia Y., Kim, Ji Eun, Askarian-Amiri, Marjan, Rewcastle, Gordon W., Finlay, Graeme J., Baguley, Bruce C.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2014
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4149495/
https://ncbi.nlm.nih.gov/pubmed/25170609
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0105792
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!